2006 Interview with: Harry S. Palmin, President and CEO - featuring: their oxidized glutathione-based compounds for the treatment of cancer and hepatitis.

Novelos Therapeutics, Inc. (OTCBB: NVLT)

CURRENT ISSUE    |   COVER ARCHIVES    |       INDEX      |    CONTACT    |    FINANCIALS    |     MARKETING SERVICES   |    HOME PAGE

CEOCFO-Members Login
Become A Member!

This is a printer friendly page!

Novelos Therapeutics lead compound offers a unique clinically proven proposition in the fight against cancer by potentiating chemotherapy as well as protecting from its toxicity, with a pivotal Phase 3 trial in lung cancer, other Phase 2s, and a potential dirty bomb application



Healthcare
Biotech/Pharma
(OTCBB: NVLT)

Novelos Therapeutics, Inc.



Harry S. Palmin
President and CEO

Interview xonducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
July 20, 2006

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“We have a unique proposition and novel technology, with NOV-002, our lead Phase 3 cancer product, which is already approved in Russia for treatment of solid tumors in cancer patients. Chemotherapy is great at killing cancer; unfortunately, chemotherapy also kills the patient. When patients take our drug NOV-002, together with the chemotherapy, not only is NOV-002 protecting from typical side-effects of chemotherapy, but its also potentiating chemotherapy - in that we are getting better survival outcome as well as better anti-tumor effects. A drug that can do both, safely with low cost, is a truly unique proposition in the market today.” - Harry S. Palmin